Elevated histone H3 acetylation is associated with genes involved in T lymphocyte activation and glutamate decarboxylase antibody production in patients with type 1 diabetes

Yanfei Wang1,2, Can Hou3*, Jonathan Wisler4, Kanhaiya Singh5, Chao Wu1,2, Zhiguo Xie1,2, Qianjin Lu6, Zhiguang Zhou1,2

1Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, 2Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, National Clinical Research Center for Metabolic Diseases, 3Department of Intensive Care Unit, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China, 4Department of Surgery, Division of Trauma, Critical Care and Burn Surgery, 5Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA, and 6Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

Keywords
CD4+ T lymphocytes, Histone H3 acetylation profile, Type 1 diabetes

*Correspondence
Can Hou
Tel.: +86-135-4856-3463
Fax: +86-731-8529-4018
E-mail address: houcan84@csu.edu.cn

J Diabetes Investig 2019; 10: 51–61
doi: 10.1111/jdi.12867

ABSTRACT

Aims/Introduction: Genetic and epigenetic mechanisms have been implicated in the pathogenesis of type 1 diabetes, and histone acetylation is an epigenetic modification pattern that activates gene transcription. However, the genome-wide histone H3 acetylation in new-onset type 1 diabetes patients has not been well described. Accordingly, we aimed to unveil the genome-wide promoter acetylation profile in CD4+ T lymphocytes from type 1 diabetes patients, especially for those who are glutamate decarboxylase antibody-positive.

Materials and Methods: A total of 12 patients with new-onset type 1 diabetes who were glutamate decarboxylase antibody-positive were enrolled, and 12 healthy individuals were recruited as controls. The global histone H3 acetylation level of CD4+ T lymphocytes from peripheral blood was detected by western blot, with chromatin immunoprecipitation linked to microarrays to characterize the promoter acetylation profile. Furthermore, we validated the results of particular genes from chromatin immunoprecipitation linked to microarrays by using chromatin immunoprecipitation quantitative polymerase chain reaction, and analyzed the transcription level by real-time quantitative polymerase chain reaction.

Results: Elevated global histone H3 acetylation level was observed in type 1 diabetes patients, with 607 differentially acetylated genes identified between type 1 diabetes patients and controls by chromatin immunoprecipitation linked to microarrays. The hyper-acetylated genes were enriched in biological processes involved in immune cell activation and inflammatory response. Gene-specific assessments showed that increased transcription of inducible T-cell costimulator was in concordance with the elevated acetylation in its gene promoter, along with positive correlation with glutamate decarboxylase antibody titer in type 1 diabetes patients.

Conclusions: The present study generates a genome-wide histone acetylation profile specific to CD4+ T lymphocytes in type 1 diabetes patients who are glutamic acid decarboxylase antibody-positive, which is instrumental in improving our understanding of the epigenetic involvement in autoimmune diabetes.

Received 12 February 2018; revised 16 May 2018; accepted 18 May 2018
INTRODUCTION
Type 1 diabetes is an organ-specific autoimmune disease triggered by immune attack of self-pancreatic β-cells. The disastrous self-destructive manner is mainly caused by T cell-mediated immunity and leads to rapid β-cell dysfunction. As such, patients with type 1 diabetes usually suffer from rapid decay of islet function and require lifelong insulin replacement therapy. In a recent study of type 1 diabetes, Weng et al. showed that the incidence of type 1 diabetes in China had increased almost fourfold in children aged <15 years in the past 30 years. However, this situation is going to continually deteriorate, as there is no effective therapy to cure type 1 diabetes so far. It is therefore of great importance to unravel the concealing mechanisms and find potential therapeutic ways to treat type 1 diabetes.

Genetic factors are largely involved in the pathogenesis of type 1 diabetes, especially the human leukocyte antigen (HLA) genes located on chromosome 6, which contribute to 40–50% of the genetic susceptibility. However, numerous studies showed that the genetic factors could not fully explain the progression of type 1 diabetes. A follow-up study of monozygotic twins showed that the onset of type 1 diabetes was not always in concordance, even with an identical genetic background, and there is only a small fraction of genetically susceptible individuals that progress to diabetes. In addition, the continual increase of the incidence of type 1 diabetes is also accompanied by rapid social development and lifestyle changes in modern society. All these suggest that there are some factors beyond genetics that are involved in the pathogenesis of type 1 diabetes. In recent years, environmental factors have been found to be able to alter gene expression through epigenetic mechanisms that could regulate gene expression without changes in deoxyribonucleic acid (DNA) sequence, mainly including DNA methylation, histone modification and non-coding ribonucleic acid (RNA). Extensive evidence has shown that lifestyle change and environmental exposure contribute to the increasing incidence of type 1 diabetes through remodeling the epigenetic modification in particular genes.

Histone acetylation is a critical pattern of histone post-translational modification, with histone acetyltransferases and deacetylases modifying the histone acetylation status in the nucleosomal core in a dynamic and reversible manner to regulate the activity of genes by unfolding or condensing the chromatin. Generally, histone acetylation could lead to gene transcriptional activation, whereas histone deacetylation causes gene silencing. Histone acetylation has been found to regulate inflammatory gene expressions and is associated with the progression of autoimmune diseases. In autoimmune diabetes, the global histone acetylation has been shown to be elevated in patients. Also, enhanced histone acetylation at promoters has been observed with an increased expression of inflammatory genes in diabetic complications. Remarkably increased histone H3 lysine 9 acetylation, a gene transcription activated marker, has been observed at the promoters of type 1 diabetes susceptible genes in monocytes from type 1 diabetes patients.

Type 1 diabetes is characterized by T lymphocytes-mediated destruction of pancreatic β-cells, and CD4+ T lymphocytes are important in recognizing islet autoantigens, especially hybrid insulin peptides and proinsulin, and prompting pancreatic infiltration in autoimmune diabetes. Aside from T cell-mediated immunity, the destruction of β-cells also leads to a humoral response with production of antibodies against β-cell autoantigens, with glutamic acid decarboxylase antibody (GADA) being the most common antibody present in autoimmune diabetes. Although histone acetylation alteration in a limited set of genes has been investigated in immune cells from type 1 diabetes patients, the genome-wide status of acetylated histone H3 on promoters and its association with gene expression have never been studied in CD4+ T lymphocytes from type 1 diabetes patients, especially for those who are GADA-positive. To this end, the present study aimed to compare the genome-wide histone H3 acetylation (H3Ac) profile of CD4+ T lymphocytes from GADA-positive type 1 diabetes patients and healthy individuals, and to find correlations between histone H3 acetylation and the pathogenesis of type 1 diabetes.

METHODS
Study participants
A total of 12 type 1 diabetes patients were recruited from The Second Xiangya Hospital of Central South University (Changsha, Hunan, China) according to the following criteria: (i) diabetes diagnosed according to World Health Organization criteria in 1999; (ii) acute-onset ketosis or ketoacidosis with immediate insulin replacement therapy; (iii) positive for GADA; (iv) diabetes diagnosed within the past 12 months; and (v) with insulin as the only medication for glucose management. The patients enrolled were free of other autoimmune diseases and did not receive any immunomodulatory drugs. A total of 12 age- and sex-matched healthy controls were enrolled, who showed euglycemia in a standardized 75-g oral glucose tolerance test and had no history of autoimmune-related disease. The study was approved by the Human Ethics Committee of The Second Xiangya Hospital of Central South University. Written informed consent was obtained from all participants. The study was carried out in accordance with the principles of the Helsinki Declaration. Study physicians recorded the participants’ height, weight and blood pressure. Fasting venous blood samples were tested for complete blood count, fasting blood sugar, hemoglobin A1C, fasting C-peptide and GADA titer. A standard 466.3 kcal, mixed-meal tolerance test (60.0% of calories as carbohydrate, 26.1% as fat and 13.9% as protein) was administered to type 1 diabetes patients. The 2-h blood sugar and 2-h C-peptide were measured 2 h post the standard meal in patients.

GADA assays
GADA was detected by radioligand assay. The GADA titer of <18 units/mL was defined as positive in a duplicate test. The
sensitivity and specificity of GADA by this assay were 82% and 97.8%, respectively. The assay was sponsored by the Immunology of Diabetes Society, and with validation by the Islet Autoantibody Standardization Program 2016.

Isolation of CD4+ T lymphocytes
Venous blood samples from participants (60 mL per participant) in the fasting condition were drawn and sodium heparin, an anticoagulant, was added. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll–Hypaque (GE Healthcare, Pittsburgh, PA, USA) density-gradient centrifugation. Approximately, 60 million PBMCs were collected from 60 mL of venous blood. CD4+ T lymphocytes were isolated by CD4+ selection using magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany), and 20–25 million CD4+ T lymphocytes were magnetically separated from PBMCs in each participant. The purity of CD4+ T lymphocytes (CD3+ CD4+ cells) was >95%, confirmed by flow cytometry (BD FACSCanto II; BD Biosciences, San Jose, CA, USA).

Western blot
Total protein was extracted from 10 million CD4+ T lymphocytes from 12 type 1 diabetes patients and 12 healthy controls separately. Protein concentration was detected using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes. The membranes were then incubated at 4°C overnight with the anti-actin-H3 antibody at 1:10,000 dilution (#06-599, Millipore, Billerica, MA, USA) and anti-histone H3 antibody at 1:5,000 dilution (#ab1791; Abcam, Cambridge, UK), followed by incubation with goat anti-rabbit immunoglobulin G. The protein bands were detected using Image LabTM Software (Bio-Rad Laboratories, Hercules, CA, USA). β-Actin was used as an internal reference for protein loading.

Chromatin immunoprecipitation linked to microarray assay
The DNA immunoprecipitate samples were pooled from four type 1 diabetes patients or five healthy controls in equal quantites of CD4+ T lymphocytes in total. One pooled sample consisting of 3 million mixed CD4+ T lymphocytes was used for sonication. Sonicate cell lysate was divided into three aliquots, and one aliquot contained approximately 1 million cell equivalent of chromatin, which was used for immunoprecipitation with 5.0 µg anti-acetyl histone H3 antibody (#06-599; Millipore). Before the antibody was added, 10 µL of the sonicate cell lysate supernatant was removed as input. The EZ ChIP™ Chromatin Immunoprecipitation Kit (#17-371, Millipore) was used to carry out the chromatin immunoprecipitation (Chip) assay and DNA purification. DNA was amplified with the Whole Genome Amplification kit from Sigma-Aldrich (Darmstadt, Germany). Fluorescent labeling of the DNA was carried out using the NimbleGen Dual-Color DNA Labeling Kit (F. Hoffman-La Roche Ltd., Basel, Switzerland). Each pooled sample was labeled and hybridized to Roche Nimblegen human 720K RefSeq promoter tiling arrays, with probes designed to cover –3,200–800 bp regions relative to the transcription start sites of 22,542 RefSeq genes, to detect sheared DNA pulled down by acetyl-H3 antibody at promoter regions. Hybridizations were carried out by KangChen Bio-tech Inc. (Shanghai, China).

Differentially acetylated genes identification and bioinformatics analysis
To identify differentially enriched regions (also called peaks), the log2 ratio values for each pooled sample (type 1 diabetes [T1D] and healthy controls [HC]) were averaged and the C value was calculated (\(C' = \text{average} [\log2 \text{ChIP}_{T1D} / \text{Input}_{T1D}] – \text{average} [\log2 \text{ChIP}_{HC} / \text{Input}_{HC}]\)) for each probe. The NimbleScan permutation-based peak-finding algorithm on these data was run to find the differential enrichment peaks. The differential enrichment peaks were filtered according to the following criteria: (i) at least one of the two groups had a median \(\log2\) ChIP / Input \(\geq 0.3\) and median \(|C'|\geq 0; and (ii) at least half of the probes in a peak might have a coefficient of variability \(\leq 0.8\) in both two samples. Multiple testing was carried out to adjust the \(P\)-value to the false discovery rate, and genes with a false discovery rate \(\leq 0.05\) were identified as the significant differentially acetylated genes (DAGs). The DAGs were then submitted to Gene Ontology (GO; http://www.geneontology.org), a community-based bioinformatics resource providing a comprehensive source for functional genomics\(^{20,21}\), to identify the enriched biological process. The \(P\)-value denoted the significance of enriched GO terms, and a \(P\)-value \(\leq 0.05\) was potentially significant and interesting.

Acetylation status validation and transcriptional activity detection
ChIP was carried out to pull down the acetylated DNA of CD4+ T lymphocytes in 12 independent type 1 diabetes patients and 12 healthy controls, respectively. Sequencing primers used in ChIP quantitative polymerase chain reaction (qPCR) on the inducible T-cell costimulator (ICOS) promoter were designed according to the position of the differential enrichment peak from ChIP linked to microarrays (Chip-chip) and were as follows: (i) –137/–55 FP 5’-GCATCAAGAAGAAACCCCC-3’, RP 5’-TGCTGGAAAGGAATGGTT-3’; (ii) –5/+78 FP 5’-ACAACCGAGACCTGAATT-3’, RP 5’-CCTGACATCCTGT-3’; (iii) +196/+280 FP 5’-TAGGACC-CAAAAGACAGTG-3’, RP 5’-TGCCATCCACAGTGACATG-3’. RNA isolation from CD4+ T lymphocytes, complementary DNA synthesis and real-time qPCR were carried out as previously described\(^{22}\). Primers for amplifying the ICOS transcript were FP 5’-GGCCAACATTACTTCTGCAACCT-3’ and RP 5’-CAGCAAAGGCTGACATC-3’. Real-time qPCR was carried out by ABI 7900HT (ABI, Foster City, CA, USA). β-Actin was used as an internal control. Data shown (mean ± standard error of the mean) were from PCRs of 12 independent patient samples with each sample run in triplicate.
Statistical analysis
Data are presented as mean ± standard error of the mean. Logarithmic transformations were applied for non-normally distributed parameters before statistical tests. Independent samples t-test was used for measurement data between two groups. A χ²-test was used to compare categorical variables. SPSS version 24.0 (IBM Corporation, Chicago, IL, USA) software was used for the statistical analysis. GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) software was used for graphical display. Differences were considered significant at a two-tailed P < 0.05.

RESULTS
Elevated histone H3 acetylation level in CD4⁺ T lymphocytes from type 1 diabetes patients

The general characteristic of type 1 diabetes patients and healthy controls are presented by group in Table 1. Age, sex, body mass index and blood pressure are comparable between two groups. To exclude individuals potentially affected by bacteria or a virus, all participants enrolled in the study had a normal complete blood count including white blood cells, neutrophils and lymphocytes. The western blot result showed that the H3Ac level in CD4⁺ T lymphocytes was significantly elevated in type 1 diabetes patients compared with healthy controls (P = 0.008; Figure 1a,b). In order to ascertain whether this change was secondary to hyperglycemia, subgroup analysis was carried out and no significant difference was found in the global acetylation level between the well- and poorly-controlled type 1 diabetes patients (Figure 1c). In addition, the global acetylation level did not correlate with the GADA titer in type 1 diabetes patients (Figure 1d).

Differentially acetylated genes are involved in critical biological processes

As elevated global H3Ac levels had been observed in type 1 diabetes, we then sought to uncover the genome-wide H3Ac alteration profile in type 1 diabetes patients. The human 720K RefSeq promoter tiling arrays were used to meet our goal and the ChiP-chip experiment flow was carried out, as shown in Figure 2a. From the ChiP-chip assay, we identified 607 DAGs between type 1 diabetes patients and healthy controls (Figure 2b). Among the DAGs, there were 317 hyperacetylated genes and 282 hypoacetylated genes in type 1 diabetes patients compared with controls. The eight genes overlapping in a Venn diagram indicated discordant acetylation alterations in different regions of the gene promoters.

The DAGs were submitted to GO, to statistically highlight the most enriched biological annotation. Fold enrichment score was used to measure the magnitude of enrichment. GO analysis showed that the hyperacetylated genes in type 1 diabetes patients were associated with innate and adaptive immune cell responses, including leukocyte degranulation, mast cell activation and T lymphocyte costimulation, and inflammatory response to antigen or cytokines (Figure 3a). In the annotation terms of hypoacetylated genes (Figure 3b), many genes were linked to other patterns of epigenetic modification, such as genetic imprinting, deubiquitination, methylation and chromatin remodeling. Furthermore, the hypoacetylated genes were clustered to the transforming growth factor beta (TGF-β) production.

Immune-related genes show hyperacetylation in promoters

According to gene function and GO, genes in DAGs closely related to innate and adaptive immunity were selected and

Table 1 | Clinical and laboratory characteristics of participants

|                      | T1D patients (n = 12) | Healthy controls (n = 12) | P-value |
|----------------------|-----------------------|--------------------------|---------|
| Age (years)          | 27.8 ± 1.6            | 28.7 ± 1.3               | 0.694   |
| Sex (male/female)    | 6/6                   | 6/6                      | 1.000   |
| Duration (months)    | 4.7 ± 0.6             | NA                       |         |
| BMI (kg/m²)          | 19.69 ± 0.70          | 21.15 ± 0.48             | 0.100   |
| SBP (mmHg)           | 108.1 ± 4.0           | 110.2 ± 2.9              | 0.676   |
| DBP (mmHg)           | 71.8 ± 2.8            | 69.3 ± 1.6               | 0.641   |
| FBS (mmol/L)         | 8.11 ± 1.00           | 4.78 ± 0.13              | 0.003   |
| 2-h BS (mmol/L)      | 12.09 ± 1.93          | 5.16 ± 0.31              | 0.002   |
| HbA1c (%)            | 8.52 ± 0.80           | 5.24 ± 0.08              | 0.001   |
| FCP (pmol/L)         | 153.07 ± 18.7         | 346.82 ± 15.14           | <0.001  |
| 2-h CP (pmol/L)      | 308.00 ± 50.52        | 1540.93 ± 143.43         | <0.001  |
| GADA (U/mL)          | 570.28 ± 111.12       | NA                       |         |
| WBC (×10⁹/L)         | 5.76 ± 0.63           | 5.48 ± 0.23              | 0.690   |
| Neutrophil (×10⁹/L)  | 3.74 ± 0.5            | 3.39 ± 0.19              | 0.521   |
| Lymphocyte (×10⁹/L)  | 1.59 ± 0.12           | 1.67 ± 0.17              | 0.722   |

Data are shown as mean ± standard error of the mean. BMI, body mass index; BS, blood sugar; CP, C-peptide; DBP, diastolic blood pressure; FCP, fasting C-peptide; GADA, glutamic acid decarboxylase; HbA1c, hemoglobin A1C; NA, not appropriate; SBP, systolic blood pressure; T1D, type 1 diabetes; WBC, white blood cells.
shown in Table 2, and were ranked by the peak score. Judging from the positive or negative value of the peak score, the number of hyperacetylated genes was significantly greater than that of hypoacetylated genes in type 1 diabetes patients. This result was consistent with the increased H3Ac in type 1 diabetes patients, as shown previously (Figure 1a,b). Among the DAGs listed, TIA1 (TIA1 cytotoxic granule-associated RNA binding), ICOS, HLA-DRB5 (major histocompatibility complex, class II, DR), FASLG (fas ligand) and so on are directly related with lymphocyte activation. Other genes from DAGs listed in Table 2 also had functions closely linked to immunity regulation.

Histone H3 acetylation of the ICOS promoter is associated with the GADA titer

In the present study, we found that the inducible T-cell costimulator, ICOS, showed hyperacetylation in the gene promoter in type 1 diabetes patients, and ICOS was enriched in the T lymphocyte costimulation term with the highest fold enrichment. Therefore, we identified ICOS as the candidate gene for further study. To gain insight into the relationship between gene expression and acetylation modification, and their impact on type 1 diabetes, we carried out the immunoprecipitation assay and total RNA extraction from CD4+ T lymphocytes from 12 type 1 diabetes patients and 12 healthy controls.

The acetylation level of the ICOS promoter was shown to be upregulated in type 1 diabetes patients compared with healthy controls, with significantly elevated acetylation occurring in region -137/-55 (1.00 ± 0.20 vs 1.73 ± 0.26, P = 0.036; Figure 4a). Compared with the healthy controls, the expression of ICOS messenger RNA (mRNA) was significantly enhanced in type 1 diabetes patients (1.00 ± 0.10 vs 1.85 ± 0.30, P = 0.013; Figure 4b). Correlation analysis showed that the acetylation level at the ICOS promoter (region -137/-55) was positively correlated with the mRNA expression (r = 0.655, P = 0.021) in type 1 diabetes patients (Figure 4c). Furthermore, bivariate correlation analysis was carried out between the expression of ICOS mRNA and clinical parameters, such as glucose level, hemoglobin A1C, C-peptide, GADA titer or blood pressure. The correlation analysis showed that the GADA titer in type 1 diabetes patients was positively correlated with the expression of ICOS mRNA (r = 0.588, P = 0.044; Figure 4d).
DISCUSSION
Epigenetic modifications regulate the expression of genes without changing the DNA sequences, thus affecting important biological processes and disease phenotypes. Accordingly, we used the ChIP-chip method to dissect the whole-genome histone H3 acetylation profile in type 1 diabetes patients. To the best of our knowledge, the present investigation is the first genome-wide epigenetic study applied to purified CD4+ T lymphocytes from GADA-positive type 1 diabetes patients. The present findings generated differentially acetylated gene sets that participated in crucial biological processes, with emphasis on an important T-cell costimulator, ICOS.

Given that the histone acetylation is a dynamic and cell-specific process, CD4+ T lymphocytes rather than PBMCs mixture were isolated from peripheral blood in the present study. As a wide range of autoimmune disease or subtle stimuli have been found to be associated with epigenetic changes, we enrolled patients with new-onset diabetes without complications and with insulin as the only medication. Covariates including age, sex and body mass index were well matched with controls, allowing for a more accurate determination of the acetylation pattern specific to type 1 diabetes rather than physiological causes. We identified evaluated global H3Ac in GADA-positive type 1 diabetes patients in our study, which was consistent with a previous observation in type 1 diabetes patients. However,
inconsistency existed in that reduced global H3Ac was observed in patients with latent autoimmune diabetes in adults. That type 1 diabetes is clinically distinct from latent autoimmune diabetes in adults might explain the discrepancy. Also, the latent autoimmune diabetes in adults study included patients with much longer disease duration, and many of them had diabetic complications that might contribute to lower acetylation, whereas the present study included only new-onset type 1 diabetes patients. Furthermore, we found that the acetylation of the ICOS promoter, rather than global acetylation, was associated with the GADA titer in type 1 diabetes patients.

The present study showed that blood glucose level had no effect on the global acetylation level. Additionally, an epigenetic study in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort showed no difference in the number of hyperacetylated regions of type 1 diabetes susceptible genes in an in vitro study. This found that changes in global acetylation from lymphocytes might be associated with autoimmune disturbance in type 1 diabetes instead of being secondary to hyperglycemia. ChIP-chip has further identified post-translational modifications in cell models cultured with high glucose or in patients with long enduring type 1 diabetes. The present study yielded a bundle of hyperacetylated genes implicated in innate and adaptive immune-related biological processes, which might reflect the initial epigenetic state in new-onset type 1 diabetes patients. Due to the gene transcriptional activation by acetylation, the T lymphocytes transcriptome could be strikingly activated in particular gene sets to exert its pathogenically attacking manner to the islet β-cells.

According to our GO analysis, hyperacetylated DAGs were engaged in T lymphocytes/leukocyte/mast cell activity, inflammatory response and cellular response to interleukin-1. Furthermore, previous studies have discerned that aberrant histone acetylation or dysregulation of gene expression through histone acetylation contributes to the pathogenesis of autoimmune diabetes. Herein, the critical gene ICOS, a gene with remarkable
acetylated alteration and highest fold enrichment in GO analysis, was selected for further study. ICOS, an inducible T-cell costimulator, is a member of the T cell-specific cell-surface receptors CD28/CTLA-4 family. The activation of T cells is mediated by the two-signal model\(^3\): the T-cell receptor recognized the peptide presented by major histocompatibility complex molecule anchoring in the surface of antigen presentation cells, accompanying the ensuing combination of costimulators as a second signal. ICOS is expressed de novo after T cells are stimulated, and promotes T-cell activation and differentiation\(^3\). Previous studies have shown that the ablation of ICOS mitigates the severity of insulitis and protects non-obese diabetic mice from spontaneous type 1 diabetes\(^3\). This indicates that ICOS is required for insulitis development and the subsequent overt autoimmune diabetes.

Follicular helper T cells (Tfh), a CD4\(^+\) T-cell subset expressing ICOS and CXCR5, are predominantly important for antibody production by plasma B cells\(^3\). In systemic lupus erythematosus, the accumulation of pathogenic autoantibodies results in multiple organ dysfunction\(^3\). With respect to autoimmune diabetes, it is well established that the islet autoantibodies are biomarkers for diagnosis without pathogenicity\(^3\). Nevertheless, the GADA titer might reflect the strength of immune response\(^3\), and be associated with the decay rate of islet function\(^3\). Many studies have shown that Tfh cells are involved

![Figure 4](http://wileyonlinelibrary.com/journal/jdi)

**Figure 4** | Histone H3 acetylation of the ICOS promoter was associated with the glutamic acid decarboxylase antibody (GADA) titer in type 1 diabetes patients (T1D). (a) The histone H3 acetylation level of the ICOS promoter was significantly enhanced in type 1 diabetes patients (n = 12) compared with healthy controls (HC; n = 12) in promoter region -137/-55, which was detected by chromatin immunoprecipitation quantitative polymerase chain reaction and data were shown as mean ± standard error of the mean, *p < 0.05. (b) Type 1 diabetes patients showed increased ICOS messenger ribonucleic acid (mRNA) level. Total RNAs were prepared from the CD4\(^+\) T lymphocytes from 12 individual patients or controls. β-Actin was used as an internal control. Data shown were from quantitative polymerase chain reactions from 12 individual participants with each sample run in triplicate. (c) Correlation analysis showed that histone H3 acetylation in the ICOS promoter (region -137/-55) was positively correlated with the expression of its mRNA in CD4\(^+\) T lymphocytes from type 1 diabetes patients. (d) The GADA titer was positively related to the ICOS mRNA level in type 1 diabetes patients.
in islet antibodies production in type 1 diabetes. The frequency of circulating activated Tfh cells was increased in children with type 1 diabetes positive for multiple autoantibodies. Meanwhile, decreased levels of autoantibodies were found in ICOS+/− non-obese diabetic mice. To replenish these observations, the expression of ICOS was confirmed in type 1 diabetes patients. The high GADA titer might partly result from elevated ICOS, which is mostly expressed in the Tfh cell, thus prompting T lymphocytes to kill more β-cells, and stimulating more B cells differentiating into plasma cells to produce autoantibodies after binding to ICOS ligand on the surface of B cells.

As for the hypoacetylated counterpart, genes engaging in other patterns of epigenetic modification showed reduced acetylation levels in the present study. This could be explained by the well-established theory that epigenetic mechanisms have a mutual effect on each other to regulate gene expression. In addition, TGF-β maintains the immune homeostasis by inhibiting pro-inflammatory cytokines secretion and controlling peripheral T-cell tolerance. The present finding provided clues that the hypoacetylated alteration on genes linked to the TGF-β production might result in being a causative element for the decreased circulating TGF-β in type 1 diabetes patients. Interestingly, several diabetes susceptible or T-cell activity-related genes – HLA-DRB5, FASLG, TNFRSF9 and NFKB1 – showed altered acetylation levels in the present study. We conjectured that dysregulation of histone acetylation might disequilibrate the immune tolerance and be inclined to activate the diabetogenic T cells in type 1 diabetes.

A genome-wide association study reported a type 1 diabetes-related single-nucleotide polymorphism, rs478222, residing in the intron of gene EFR3B. The DAGs in the present study also included the gene, EFR3B, with its promoter presenting altered acetylation levels in the present study. We conjectured that dysregulation of histone acetylation might dissequilibrate the immune tolerance and be inclined to activate the diabetogenic T cells in type 1 diabetes.

ACKNOWLEDGMENTS

We thank Mr Fajun Han, a data miner engineer from Kang-Chen Bio-tech Inc., for constructive advice and carrying out the bioinformatics analysis. The authors thank all the participants for their cooperation and devotion in this study, and acknowledge the study nurse, Xiaoping You, for helping with the sample collection. This study was supported by grants from the National Science and Technology Infrastructure Program (2015BAI12B13), the National Natural Science Foundation of China (81461168031), the Key Project of Chinese Ministry of Education (113050A), the National Natural Science Foundation of China (81200580), the Doctoral Fund of Ministry of Education of China (20120162120090), the Hunan Provincial Natural Science Foundation of China (14JJ3042), the Fundamental Research Funds for the Central Universities of Central South University (502221703) and China Scholarship Council (201606375127).

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383: 69–82.
2. Weng J, Zhou Z, Guo L, et al. Incidence of type 1 diabetes in China, 2010–13: population based study. BMJ 2018; 360: j5295.
3. Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med 2012; 2: a007732.
4. Hytinen V, Kaprio J, Kinnunen L, et al. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 2003; 52: 1052–1055.
5. Peng H, Hagopian W. Environmental factors in the development of Type 1 diabetes. Rev Endocr Metab Disord 2006; 7: 149–162.
6. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science 2010; 330: 612–616.
7. Wang Z, Xie Z, Lu Q, et al. Beyond genetics: what causes type 1 diabetes. Clin Rev Allergy Immunol 2017; 52: 273–286.
8. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349–352.
9. Zhao M, Huang W, Zhang Q, et al. Aberrant epigenetic modifications in peripheral blood mononuclear cells from patients with pemphigus vulgaris. Br J Dermatol 2012; 167: 523–531.
10. Hu N, Long H, Zhao M, et al. Aberrant expression pattern of histone acetylation modifiers and mitosis of lupus by SIRT1-siRNA in MRL/lpr mice. Scand J Rheumatol 2009; 38: 464–471.
11. Chen SS, Jenkins AJ, Majewski H. Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients. *Diabet Med* 2009; 26: 182–186.

12. Zeng J, Chen B. Epigenetic mechanisms in the pathogenesis of diabetic retinopathy. *Ophthalmologica* 2014; 232: 1–9.

13. Miao F, Chen Z, Zhang L, et al. Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes. *J Biol Chem* 2012; 287: 16335–16345.

14. Delong T, Wiles TA, Baker RL, et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. *Science* 2016; 351: 711–714.

15. Stifter K, Schuster C, Schlosser M, et al. Exploring the induction of preproinsulin-specific Foxp3(+) CD4(+) T cells that inhibit CD8(+) T cell-mediated autoimmune diabetes by DNA vaccination. *Sci Rep* 2016; 6: 29419.

16. von Herrath M. Immunology: insulin trigger for diabetes. *Nature* 2005; 435: 151–152.

17. Gu Y, Zhang M, Chen H, et al. Discordant association of islet autoantibodies with high-risk HLA genes in Chinese type 1 diabetes. *Diabetes Metab Res Rev* 2011; 27: 899–905.

18. Li X, Huang G, Lin J, et al. Variation of C peptide decay rate in diabetic patients with positive glutamic acid decarboxylase antibody: better discrimination with initial fasting C peptide. *Diabetes Res Clin Pract* 2013; 13: 10.

19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; 15: S39–S53.

20. Blake JA, Dolan M, Drabkin H, et al. Gene ontology annotations and resources. *Nucleic Acids Res* 2013; 41: D530–D535.

21. Gene Ontology Consortium. Going forward. *Nucleic Acids Res* 2015; 43: D1049–D1056.

22. Li Y, Zhao M, Hou C, et al. Abnormal DNA methylation in CD4+ T cells from people with latent autoimmune diabetes in adults. *Diabetes Res Clin Pract* 2011; 94: 242–248.

23. Adachi S, Rothenberg EV. Cell-type-specific epigenetic marking of the IL2 gene at a distal cis-regulatory region in competent, nontranscribing T-cells. *Nucleic Acids Res* 2005; 33: 3200–3210.

24. Wang Z, Chang C, Lu Q. Epigenetics of CD4+ T cells in autoimmune diseases. *Curr Opin Rheumatol* 2017; 29: 361–368.

25. Ding R, Jin Y, Liu X, et al. Dose- and time- effect responses of DNA methylation and histone H3K9 acetylation changes induced by traffic-related air pollution. *Sci Rep* 2017; 7: 43737.

26. Liu XY, Xu JF. Reduced histone H3 acetylation in CD4(+) T lymphocytes: potential mechanism of latent autoimmune diabetes in adults. *Dis Markers* 2015; 2015: 285125.

27. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. *Nat Rev Endocrinol* 2017; 13: 674–686.

28. Miao F, Chen Z, Genuith S, et al. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. *Diabetes* 2014; 63: 1748–1762.

29. Miao F, Wu X, Zhang L, et al. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. *J Biol Chem* 2007; 282: 13854–13863.

30. Miao F, Smith DD, Zhang L, et al. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. *Diabetes* 2008; 57: 3189–3198.

31. Hou C, Zhong Y, Wang Z, et al. STAT3-mediated epigenetic silencing of FOXP3 in LADA T cells is regulated through HDAC5 and DNMT1. *Clin Immunol* 2017; 191: 116–125.

32. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. *Proc Natl Acad Sci USA* 1999; 96: 185–190.

33. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. *Nature* 1999; 397: 263–266.

34. Hawiger D, Tran E, Du W, et al. ICOS mediates the development of insulin-dependent diabetes mellitus in nonobese diabetic mice. *J Immunol* 2008; 180: 3140–3147.

35. Kadri N, Korpos E, Gupta S, et al. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. *J Immunol* 2012; 188: 3138–3149.

36. Crotty S. T follicular helper cell differentiation, function, and roles in disease. *Immunity* 2014; 41: 529–542.

37. Iwai H, Abe M, Hirose S, et al. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. *J Immunol* 2003; 171: 2848–2854.

38. Jaeckel E, Klein L, Martin-Orozco N, et al. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. *J Exp Med* 2003; 197: 1635–1644.

39. Liu L, Li X, Xiang Y, et al. Latent autoimmune diabetes in adults with low-titer GAD antibodies: similar disease progression with type 2 diabetes: a nationwide, multicenter prospective study (LADA China Study 3). *Diabetes Care* 2015; 38: 16–21.

40. Huang G, Yin M, Xiang Y, et al. Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3-year follow-up. *Diabetes Metab Res Rev* 2016; 32: 615–622.

41. Viisanen T, Illantola EL, Nanto-Salonen K, et al. Circulating CXCR5 + PD-1 + ICOS+ follicular T helper cells are increased close to the diagnosis of type 1 diabetes in children with multiple autoantibodies. *Diabetes* 2017; 66: 437–447.
42. Huehn J, Beyer M. Epigenetic and transcriptional control of Foxp3+ regulatory T cells. *Semin Immunol* 2015; 27: 10–18.
43. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. *Annu Rev Immunol* 1998; 16: 137–161.
44. Abdel-Latif M, Abdel-Moneim AA, El-Hefnawy MH, et al. Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes. *Clin Exp Immunol* 2017; 190: 110–121.
45. Bradfield JP, Qu HQ, Wang K, et al. A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. *PLoS Genet* 2011; 7: e1002293.
46. Qiu YH, Deng FY, Li MJ, et al. Identification of novel risk genes associated with type 1 diabetes mellitus using a genome-wide gene-based association analysis. *J Diabetes Investig* 2014; 5: 649–656.
47. Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. *Diabetes* 2013; 62: 543–550.